Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 11;3:17058. doi: 10.1038/cddiscovery.2017.58

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Combination of aspirin and sorefenib is optimized to treatment of advanced HCC patients with high ACSL4 and low GADD45B expression. (a and b) ACSL4 high and GADD45B low in HCC tissues were significantly associated with poor overall survival (a) and recurrence-free survival (b) in our data set. The median expression value obtained for ACSL4 and GADD45B in the samples studied was chosen as the cut-off point for survival analysis using the Kaplan–Meier method. (c and d) The other HCC patients that are either low ACSL4 and low GADD45B or high ACSL4 and high GADD45B, the difference in survival was in between. (e) A schematic diagram has been put forward to summarize that silenced ACSL4 and induced GADD45B expression by aspirin and sorafenib combination is promising to treat liver cancer.